Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2017

View Archived Issues

Akebia Therapeutics obtains license to HIF-targeting products from Janssen

Mount Tam Biotechnologies advances its novel compound TAM-03 to treat a range of cancer types

Allergy Therapeutics announces CTA approval for phase I trial of house dust mite allergy vaccine

Sanofi offers overview of fourth quarter 2016

Mundipharma and Helsinn expand agreements for antiemetic drugs

Macrophage EP2/NF-kappaB pathway as a novel therapeutic target for intracranial aneurysms

Ionis Pharmaceuticals earns milestone from Bayer for advancing antisense drugs

Phase I study of Vaxart's norovirus tablet vaccine meets endpoints

FDA grants fast track designation to Axsome Therapeutics' AXS-05

Otsuka Pharmaceutical reviews milestones of fourth quarter 2016

Engineered plant cells allow protein delivery for tolerance induction for hemophilia treatment

TB Alliance describes novel compounds for tuberculosis

RCSI and Almac collaborate on treatment-resistant cancer

Armetheon receives advice from EMA on pivotal study of oral anticoagulant

Merck & Co. to stop phase II/III EPOCH study of verubecestat for lack of efficacy

Kenneth Rainin Foundation awards grants to support research into IBD

AMAG Pharmaceuticals and Endoceutics sign U.S. license agreement for Intrarosa

miR-124-3p, a potential therapeutic target and biomarker in major depressive disorder

Incyte and Agenus amend 2015 license, development and commercialization agreement

Amgen submits sBLA to FDA for Blincyto

Ardelyx's phase III trial of tenapanor meets primary endpoint

AbbVie files for Japanese approval of glecaprevir/pibrentasvir

CTHBP and IF1 as novel biomarkers of dermatomyositis

Gilead Sciences launches Vemlidy in Japan

NanoPass and IDRI to collaborate on Zika virus vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...